Insmed (INSM) Profit After Tax (2010 - 2026)
Insmed (INSM) posted quarterly Profit After Tax of -$1.5 million for Q1 2026, up 99.43% year-over-year from -$730574.3 in Q1 2025, and up 99.55% quarter-over-quarter from -$324.7 million in Q4 2025.
Analysis
Insmed (INSM) Profit After Tax (2010 - 2026) Analysis & Trends
Insmed's Profit After Tax history runs 17 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 99.43% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$693.6 million (up 31.65% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.08% from the prior year.
- Profit After Tax for Q1 2026 stood at -$1.5 million, up from -$324.7 million in the prior quarter.
- The five-year high for Profit After Tax was $562.0 million in Q4 2023, with the low at -$370.0 million in Q3 2025.
- The 5-year median for Profit After Tax is -$157.8 million (2022), against an average of -$123.1 million.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax tumbled 40517.9% in 2022, then jumped 456.22% in 2023.
- Insmed's Profit After Tax stood at -$157.8 million in 2022, then surged by 456.22% to $562.0 million in 2023, then sank by 142.19% to -$237.1 million in 2024, then slumped by 36.97% to -$324.7 million in 2025, then jumped by 99.55% to -$1.5 million in 2026.
- Business Quant data shows INSM's Profit After Tax at -$1.5 million in Q1 2026, -$324.7 million in Q4 2025, and -$370.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 585.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.62 Mn |
| Mar 31, 2026 | -165.02 Mn |
| Dec 31, 2025 | -328.50 Mn |
| Sep 30, 2025 | -370.02 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.58 Mn |
| Dec 31, 2024 | -237.09 Mn |
| Sep 30, 2024 | -220.52 Mn |
| Jun 30, 2024 | -301.80 Mn |
| Mar 31, 2024 | -157.98 Mn |
| Dec 31, 2023 | -184.73 Mn |
| Sep 30, 2023 | -159.76 Mn |
| Jun 30, 2023 | -247.14 Mn |
| Mar 31, 2023 | -159.76 Mn |
| Dec 31, 2022 | -157.98 Mn |
| Sep 30, 2022 | -131.60 Mn |
| Jun 30, 2022 | -96.34 Mn |
| Mar 31, 2022 | -95.82 Mn |
| Dec 31, 2021 | -112.89 Mn |
| Sep 30, 2021 | -113.04 Mn |